COMPARATIVE EVALUATION OF BREAST CANCER PATIENTS NEU POSITIVE HER-2 who were treated with trastuzumab chemotherapy STANDARDS AND STANDARDS WITH CHEMOTHERAPY WITHOUT trastuzumab PERIOD JANUARY 2010 - DECEMBER 2013
ABSTRACT: Background : Incidence of breast cancer in Indonesia occupied the the highest order. Her- 2/ neu is a member of c-erb B, receptor tyrosin kinase and overexpression of 20-30 % from breast cancer. Objective : To compare the overall survival and disease free survival between patients with breast cancer her - 2/neu who received standard chemotherapy trastuzumab to standard chemotherapy without trastuzumab. Subjects : Operabel breast cancer patients who underwent radical mastectomy modifications in Dr Sardjito Hospital in January 2010 - December 2013 and met the inclusion criteria. Method : This study used a retrospective cohort design. Kapplan Meyer survival test with p<0.05 considered significant. Result : Lokoregional recurrence in the group receiving trastuzumab and do not get that 2 patients (6.9%) and 12 patients (50 %). A decrease in the recurrence rate of 43.1% lokoregional, p=0.000 (CI = -0,651 to -0,211). There is a significant difference in the incidence of recurrence lokoregional value p=0.126 (log rank test) and p=0.066 (Breslow test) (p < 0.05). Distant metastases in the group receiving trastuzumab and do not get that 5 patients (17.2 %) and 9 patients (37.5 %). The presence of distant metastasis rate reduction of 20.3 %, p=0.001 (CI = -0,440 to 0,034). There was no significant difference, p=0.126 (log rank test), p=0.066 (Breslow test) (p>0.05). Mortality rate of approximately 6 patients (25 %) in the group that did not get trastuzumab and in the group receiving trastuzumab is not obtained mortality. A decrease in the mortality rate by 25 %, p=0.000 (CI = -0,423 to -0,076). There is a significant difference in the incidence of mortality, p=0.12 (log rank test) and p=0.015 (Breslow test) (p< 0.05). Clinicopathologic factors associated with the incidence of recurrence is tumor stage, lymph node positive and trastuzumab administration, associated with the incidence of metastasis was lymph node positive and associated with the incidence of mortality was positive lymph nodes, trastuzumab administration. Conclussion : Additional therapy with traztuzumab can significantly improve disease free survival and overal survival in patients with Her2/neu positive breast cancer.
ABSTRACT: Background : Incidence of breast cancer in Indonesia occupied the the highest order. Her- 2/ neu is a member of c-erb B, receptor tyrosin kinase and overexpression of 20-30 % from breast cancer. Objective : To compare the overall survival and disease free survival between patients with breast cancer her - 2/neu who received standard chemotherapy trastuzumab to standard chemotherapy without trastuzumab. Subjects : Operabel breast cancer patients who underwent radical mastectomy modifications in Dr Sardjito Hospital in January 2010 - December 2013 and met the inclusion criteria. Method : This study used a retrospective cohort design. Kapplan Meyer survival test with p<0.05 considered significant. Result : Lokoregional recurrence in the group receiving trastuzumab and do not get that 2 patients (6.9%) and 12 patients (50 %). A decrease in the recurrence rate of 43.1% lokoregional, p=0.000 (CI = -0,651 to -0,211). There is a significant difference in the incidence of recurrence lokoregional value p=0.126 (log rank test) and p=0.066 (Breslow test) (p < 0.05). Distant metastases in the group receiving trastuzumab and do not get that 5 patients (17.2 %) and 9 patients (37.5 %). The presence of distant metastasis rate reduction of 20.3 %, p=0.001 (CI = -0,440 to 0,034). There was no significant difference, p=0.126 (log rank test), p=0.066 (Breslow test) (p>0.05). Mortality rate of approximately 6 patients (25 %) in the group that did not get trastuzumab and in the group receiving trastuzumab is not obtained mortality. A decrease in the mortality rate by 25 %, p=0.000 (CI = -0,423 to -0,076). There is a significant difference in the incidence of mortality, p=0.12 (log rank test) and p=0.015 (Breslow test) (p< 0.05). Clinicopathologic factors associated with the incidence of recurrence is tumor stage, lymph node positive and trastuzumab administration, associated with the incidence of metastasis was lymph node positive and associated with the incidence of mortality was positive lymph nodes, trastuzumab administration. Conclussion : Additional therapy with traztuzumab can significantly improve disease free survival and overal survival in patients with Her2/neu positive breast cancer.
